Results 31 to 40 of about 27,503 (257)

Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario [PDF]

Journal of Clinical and Diagnostic Research, 2017
Introduction: Teneligliptin is a recently developed Dipeptidyl Peptidase 4 (DPP4) inhibitor. Teneligliptin is suitable for glycaemic control in Type 2 Diabetes Mellitus (T2DM) patients with renal impairment including end stage renal disease.
Kiran Shah
doaj   +1 more source

Dipeptidyl peptidase-4 inhibitor-related renal disease

Journal of Diabetes and its Complications, 2023
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used to treat type 2 diabetes (T2D). Lowering blood glucose is expected also to reduce the progression of diabetic nephropathy. We experienced a patient with T2D who achieved good glycemic control with a DPP-4 inhibitor but experienced rapid deterioration of renal function.
Atsuhiko, Suenaga, Naoki, Sawa, Yuki, Oba, Daisuke, Ikuma, Akinari, Sekine, Eiko, Hasegawa, Hiroki, Mizuno, Tatsuya, Suwabe, Sara, Ikeda, Tetsuro, Tsujimoto, Kei, Kono, Yukako, Shintani-Domoto, Keiichi, Kinowaki, Kenichi, Ohashi, Motoaki, Miyazono, Yutaka, Yamaguchi, Yoshifumi, Ubara   +16 more
openaire   +2 more sources

Inhibition of dipeptidyl peptidase 7 impairs lysophagy in LLOMe‐treated HepG2 cells

FEBS Letters, EarlyView.
DPP7 inhibition delays ubiquitin‐dependent lysophagy by attenuating ubiquitin accumulation and the recruitment of SQSTM1 and LC3 to damaged lysosomes, resulting in delayed clearance of damaged lysosomes and impaired restoration of lysosomal homeostasis. Created using FigureLabs (Certificate ID: FL‐PUB‐20260922‐Z99XNX).
Na Yeon Park, Inho Kwon, Yong Hwan Kim, Ji‐Eun Bae, Joon Bum Kim, Seong Hyun Kim, Sungho Maeng, Doo Sin Jo, Dong‐Hyung Cho   +8 more
wiley   +1 more source

Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

Терапевтический архив
The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase-4 inhibitor group.
Iuliia G. Samoilova, Olga E. Vaizova, Anastasia E. Stankova, Mariia V. Matveeva, Daria V. Podchinenova, Dmitry A. Kudlay, Anastasiia A. Borozinets, Tatyana A. Filippova, Ivan R. Grishkevich, Anastasia V. Partala, Diana A. Gerasimova   +10 more
doaj   +1 more source

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study

Journal of Diabetes Investigation, 2021
Aims/Introduction We recently reported the beneficial effect of the combination of sodium–glucose cotransporter 2 inhibitor and dipeptidyl peptidase‐4 inhibitor on daily glycemic variability in patients with type 2 diabetes mellitus. Additional favorable
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuno Omori, Kazuhisa Tsuchida, Aika Miya, Ikumi Shigesawa, Kenichi Tsuchida, Shingo Yanagiya, Hiraku Kameda, Hiroki Yokoyama, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Naoki Nishimoto, Tatsuya Atsumi, Hideaki Miyoshi   +20 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

An Engineered HR1‐Stem Helix‐HR2 Trimeric Platform for Developing Broad‐Spectrum Coronavirus Vaccines

Advanced Science, EarlyView.
Sun et al. report a self‐assembling trimeric subunit vaccine platform termed RHS, which integrates the JN.1 receptor‐binding domain (RBD) with the heptad repeat 1 (HR1), stem helix (SH), and heptad repeat 2 (HR2) regions. The SARS‐CoV‐2 RHS vaccine elicits variant‐reactive RBD‐specific antibodies and cross‐reactive SH‐specific antibodies against ...
Xikui Sun, Junhao Fan, Xiaolu Xie, Yuting Shi, Xiaoqing Liu, Tiefeng Xu, Sidi Yang, Keda Shi, Chengshu Xie, Shixiong Li, Siwen Chen, Ruoxi Cai, Ping He, Yuzhen Ye, Tao Chen, Xiancai Ma, Chunmei Li, Jingyou Yu, Deyin Guo   +18 more
wiley   +1 more source

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis

BMC Cancer, 2019
Background Chemotherapy-induced alimentary mucositis (AM) is difficult to prevent and treatment is rarely effective. Recent study have been showed that glucagon-like peptide (GLP)-1 and GLP-2 has protective in chemotherapy-induced AM.
Jung Min Lee, In Kyung Yoo, Jae Min Lee, Seung Han Kim, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Yoon Tae Jeen, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um, Chang Duck Kim   +12 more
doaj   +1 more source

Reframing the Gut–Brain Axis: The Gut Wall as a Neural Immune Interface in Multiple Sclerosis and Autoimmune Neurological Diseases

Annals of Neurology, EarlyView.
Gut wall physiology in multiple sclerosis (MS) and autoimmune neurologic diseases remains underexplored but may span gut barrier dysfunction, enteric glial targeting, mucosal immune dysregulation, and autoimmune targets within the enteric nervous system (ENS).
Federico Montini, Sean J. Pittock, Laura Cacciaguerra, Howard L. Weiner, Luke A. Schwerdtfeger   +4 more
wiley   +1 more source

Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats

Journal of Pharmacological Sciences, 2014
.: To clarify the role of dipeptidyl peptidase-4 (DPP-4) inhibition in vascular tissues, we compared the effects of the poorly tissue-penetrative DPP-4 inhibitor sitagliptin to the highly tissue-penetrative DPP-4 inhibitor linagliptin in Zucker diabetic ...
Shinji Takai, Hiroshi Sakonjo, Denan Jin
doaj   +1 more source